Inspection readiness doesn’t start when the auditor arrives.
Introducing the SafeCue PV Case Quality & Defensibility Assessment Pilot
In today’s regulatory environment, inspection readiness is no longer just about meeting timelines—it’s about the strength, clarity, and medical defensibility of the story your safety data tells.
At SafeCue Solutions, we see a growing challenge across small and mid-size sponsors and CROs: cases may be processed on time, but the underlying documentation often carries hidden quality risks that only surface during inspections, audits, or signal evaluations. These risks can include unclear medical narratives, inconsistent causality logic, missing rationale, and documentation that is technically complete but not inspection-defensible.
To help organizations proactively identify and address these gaps, we are launching our PV Case Quality & Defensibility Assessment Pilot, a focused, independent review designed to strengthen inspection readiness without disrupting operations.
What Is the Pilot?
This pilot provides an objective, medically-led assessment of up to 25 pharmacovigilance cases, evaluating:
Narrative clarity and clinical logic
Consistency across source, case processing, and regulatory documentation
Medical defensibility of assessments and conclusions
Common inspection-triggering weaknesses and patterns
The goal is not to reprocess cases, but to identify where documentation may be vulnerable under regulatory scrutiny—and why.
Who Is It For?
This pilot is designed for:
Small to mid-size biotech and pharmaceutical sponsors
CROs seeking an independent quality perspective
Organizations preparing for inspections, audits, or program growth
Importantly, the assessment requires no system changes and no operational disruption.
What You Receive
Participating organizations will receive a concise, actionable report that includes:
A Case Quality & Defensibility Summary
Key risk areas and recurring themes
Examples of documentation issues inspectors commonly question
Prioritized, practical recommendations
An optional discussion to align on next steps and remediation strategy
Why This Matters
Regulators don’t just review whether a case was processed, they assess whether the clinical story is coherent, consistent, and defensible. Gaps in documentation quality can lead to:
Extended inspection findings
Increased remediation burden
Delays in development or regulatory confidence
Rework that could have been avoided with early, independent review
By identifying these risks early, organizations can strengthen their safety documentation, reduce inspection stress, and build a more resilient pharmacovigilance foundation.
Our Perspective
SafeCue Solutions is a nurse-led, pharmacovigilance-focused consultancy built on the belief that quality is not just compliance, it is clarity, clinical integrity, and patient protection. This pilot reflects our commitment to helping sponsors move from “inspection ready on paper” to truly inspection defensible in practice.
If you are interested in participating in the PV Case Quality & Defensibility Assessment Pilot or would like to learn more, please contact us at contact@SafeCueSolutionsus.com.
